Medigen Vaccine Biologics Corporation

Taipei Exchange 6547.TWO

Medigen Vaccine Biologics Corporation EBITDA Margin for the year ending December 31, 2023: -254.37%

Medigen Vaccine Biologics Corporation EBITDA Margin is -254.37% for the year ending December 31, 2023, a 29.64% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Medigen Vaccine Biologics Corporation EBITDA Margin for the year ending December 31, 2022 was -361.55%, a -875.91% change year over year.
Medigen Vaccine Biologics Corporation EBITDA Margin for the year ending December 31, 2021 was 46.60%, a 101.00% change year over year.
Medigen Vaccine Biologics Corporation EBITDA Margin for the year ending December 31, 2020 was -4,654.62%, a 89.14% change year over year.
Medigen Vaccine Biologics Corporation EBITDA Margin for the year ending December 31, 2019 was -42,866.88%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Taipei Exchange: 6547.TWO

Medigen Vaccine Biologics Corporation

CEO	Leo Lee
IPO Date	Sept. 16, 2015
Location	Taiwan
Headquarters	No. 16, Hu Road
Employees	103
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

Key trends

Past 5 years